Mealey's (December 20, 2018, 9:21 AM EST) -- CHICAGO — An Illinois federal judge on Dec. 17 concluded that an abbreviated new drug application (ANDA) for dexmedetomidine products by Fresenius Kabi can proceed because two Hospira Inc. patents purportedly infringed by the proposed generic are invalid as obvious (Hospira Inc. v. Fresenius Kabi USA LLC, Nos. 16-651, 17-7903, N.D. Ill., 2018 U.S. Dist. LEXIS 212916)....